CAR T cells

In this webinar, Christoph Herbel will discuss multiplexed spatial analyses that identify ovarian tumor antigens and CAR T cell candidates.

Learn how immunotherapy is revolutionizing autoimmune disorder treatment.

Optimizing nonviral genetic engineering of resting T cells for improved cancer immunotherapy

The FOXO1 transcription factor boosts T cells’ memory and reduces dysfunction.

Multi-targeted Cas13 screens help researchers avoid permanent DNA cuts and evade T cell exhaustion.

Living drugs get a boost from emerging engineering strategies that focus on safety and specificity.

From smart receptors to novel biologics, scientists plan to overcome the challenges of treating solid tumors.

Christopher Klebanoff hopes that his search for a small fraction of cancer-specific antigens will have a big impact on cancer cell therapies.

A CRISPR-based screening platform helped scientists identify a transcription factor that makes CAR T cells better at killing cancer cells. 

Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.

In this webinar, Patrick Schmidt will explore how to streamline CAR T cell product manufacturing processes for immunotherapy. 

This year’s Breakthrough Prizes honor advances in CAR T cancer therapies, cystic fibrosis, and Parkinson’s disease.

An expert panel will discuss the interplay between cancer and the immune system, and how researchers develop immunotherapies and other immune-supporting strategies against cancer. 

From early target discovery to preclinical development stages, researchers explore novel strategies for effective cell therapies in cancer treatment.

A well-established monitoring system can ensure a constant and stable environment for CAR T cell production. 

Scientists isolate rare yet desirable CAR T cell subtypes using an innovative cell sorter system within a closed manufacturing process.

Learn about the tools and resources researchers use to define, discover, and deploy anti-tumor immunotherapies.

Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.

Researchers employ peripheral blood mononuclear cells (PBMCs) in clinical and academic applications related to the immune system and regenerative medicine.